Clinical trials: Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)
Safety and Efficacy Evaluation of CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT03229876
- Testing
- CD19-UCART
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Leukemia, Myelodysplastic Syndromes
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Trial name
- NCT00732316
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia.
- Trial name
- NCT07108010
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Assiut University
Hematologic Malignancies
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
This is a single arm pilot study for patients with hematologic malignancies with alternative donor sources receiving unrelated or partially matched related/Haploidentical mobilized peripheral stem cells (PSCs) using the CliniMACS…
- Trial name
- NCT02600208
- Testing
- CliniMACs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Julie-An M. Talano
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases.
- Trial name
- NCT02248597
- Testing
- fludarabine phosphate, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Bone Marrow Transplant Infection, Bone Marrow Transplant Complications
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
Interventional non-randomized trial. The duration of study will be 47 months. After haploidentical transplantation, patients without complications, mainly a GVHD ≥ grade 2, will receive mDLI.
- Conditions
- Bone Marrow Transplant Infection, Bone Marrow Transplant Complications, Graft Vs Host Disease, Infection
- Trial name
- NCT04687982
- Testing
- modified donor lymphocytes infusion (mDLI)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Istituto Clinico Humanitas
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed).
- Trial name
- NCT04905810
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brian Jonas
Non-Hodgkin Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
The purpose of this study is to learn about the safety and what the body does to the medicine (Maplirpacept) when taken for the treatment of non-Hodgkin lymphoma or multiple myeloma.
- Trial name
- NCT05896774
- Testing
- Maplirpacept
- Where
- 5 sites in China
- Volunteers
- 10 people
- Sponsor
- Pfizer
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure
- Trial name
- NCT03622788
- Testing
- Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Hematologic Malignancy, Haplo-identical HCT
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs.
- Trial name
- CD45RADLITx (NCT07662369)
- Testing
- CD45RA depleted donor lymphocyte infusion (DLI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Polycythemia Vera, Essential Thrombocytosis
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).
- Trial name
- NCT00586651
- Testing
- lestaurtinib
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Cephalon
Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression.
- Trial name
- NCT01062230
- Testing
- Bortezomib (Velcade)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Hematological Malignancies
Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
The goal of this prospective study is to assess the overall mortality (whether related to relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell transplantation prepared by a so-called reduced-toxicity…
- Trial name
- ITT 08-01 (NCT00841724)
- Testing
- Fludarabine, Busulfan, Thymoglobuline
- Where
- 3 sites in France
- Volunteers
- 82 people
- Sponsor
- Nantes University Hospital
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.